中新网长沙2月1日电 (记者 李俊杰)“要缓解老百姓‘看病难、看病贵’现象，需加强对生物医药行业经销商数量和质量的控制，以此来净化销售环境，回归以创新和性价比为主流的市场竞争秩序。”1日，湖南省十二届人大代表戴立忠建言，希望政府能出台监管政策，减少医药行业流通环节，从而降低药品成本。

Beijing on February 1, changsha (Reporter LiJunJie)"To alleviate people‘Difficulties in getting/The doctor your’phenomenon,Need to strengthen the biological medicine industry dealers quantity and quality control,In order to purify sales environment,Regression to innovation and price for the mainstream market competition order."1,The National People's Congress of hunan province. DaiLiZhong tips,Hope the government can come regulatory policy,Reduce the medicine circulation industry,In order to reduce the cost of drugs.

　　同时，戴立忠还认为，在创新产品的市场应用上，政府应出台一些细化和配套的支持政策。

At the same time,DaiLiZhong also believe that,In the innovation product market applications,The government should come some refining and the necessary support policy.

　　今年45岁的戴立忠系湖南宁乡人。作为中组部“国家千人人才计划”人选、湖南省“百人人才计划”首批特聘专家，2008年，戴从美国最大的一家核酸试剂公司激流勇退后，回到家乡长沙，创建了湖南圣湘生物科技有限公司，从事湖南医药创新研发。

This year at the age of 45 DaiLiZhong system ningxiang people in hunan province.As the CCCCP"National one thousand talents plan"candidate/hunan"One hundred talents plan"First distinguished experts,In 2008,,Wear from the United States is the biggest a nucleic acid reagent company lotic brave back,Back to hometown changsha,To create a hunan SAN xiang biological technology co., LTD,Engaged in hunan medical innovation research and development.

　　目前，戴立忠带领公司研发团队利用先进技术，自主研发了高精度乙肝定量PCR检测试剂。经检验后，确定该试剂准确性和稳定性均达到国际先进水平。

At present,DaiLiZhong lead the company research and development team using advanced technology,Independent research and development high precision hepatitis b quantitative PCR detection reagent.After the inspection,Determine the reagent accuracy and stability are reached the international advanced level.

　　在戴立忠看来，生物医药行业，流通环节复杂是“导致老百姓看病贵”的一个重要原因。市场上的营销，多以渠道网络和客户关系取胜，经销商掌握了巨大的市场资源，分享了利益链中最大的一块蛋糕，他们以追求商业利益为目的，不注重产品质量和性价比，加之中间环节过多，长期以往，扼杀了产业的创造性和可持续发展能力，也增加了药品成本。因此，加强对生物医药行业经销商数量控制十分必要。

In DaiLiZhong seems,Biological medicine industry,Circulation is complicated"People see a doctor to you"One of the important reasons.The market marketing,In channel network and customer relationship to win,Dealers master the huge market resources,Share the interests of the largest chain of a piece of cake,They to pursue business interests for the purpose,Don't pay attention to product quality and price,And much of the intermediate links,Long before,Kill the industrial creativity and the ability of sustainable development,Also increases the cost of drugs.so,To strengthen biological medicine industry dealers quantity control is necessary.

　　创新是企业的生命，也是企业取决于市场的制胜法宝。戴立忠藉此认为，要培育和发展战略性新兴产业，加速推进新型工业化，就要大力鼓励创新，建立与创新企业发展相适应的市场环境，扶持重大社会效益新产品市场示范应用，培育创新企业生存土壤。

Innovation is the life of enterprise,Is a magic weapon to win enterprise depends on the market.DaiLiZhong by this thought,To cultivate and develop strategic emerging industry,Accelerating the new industrialization,Will make great efforts to encourage innovation,The establishment and development of the enterprise innovation to adapt to the market environment,Support significant social benefits of new products to the market application demonstration,Cultivating innovation enterprise survival soil.

　　而湖南目前实施集中招标采购、片面强调价格因素的现状也被戴立忠列为扼杀创新型企业发展动力的原因之一。“以价低论英雄，常常要求不同质量的产品同价格，强迫产品低价中标，这是创新型企业始终难以跨越的市场壁垒。”

　　而湖南At present实施集中招标采购/The one-sided emphasis on the present situation of the price factor is also DaiLiZhong as stifle innovation enterprise development one of the reasons for the power."With low price theory hero,Often require different quality products with the price,Forced the products at a low price,This is the innovative enterprise always difficult to cross the market barriers."

　　此外，戴立忠还建议，应完善创新产品市场准入机制及招投标机制，加快解决对新产品的管理滞后，采购政策不到位等问题，加强对创新产品在市场准入的政策引导。

In addition,DaiLiZhong also suggested,We should perfect the innovative products market access mechanism and bidding mechanism,To speed up the solution to the new product management lag,Purchasing policy does not reach the designated position problems,Strengthen the innovative products in the market access policy guidance.

　　在创新产品公共采购政策方面，戴立忠建议，让生物医药领域技术含量高、性价比高、医院临床使用效率高、疗效确切，安全性高、价格合理的新产品尽早纳入国家或者省基本医疗保险、工商保险药品目录和新农村合作医疗用药目录，并通过物价管理部门的审核定价。符合政府采购的产品，优先列入政府采购范围，同时在医药招标上，在政策上给予倾斜和优先支持，从各方面推动使创新产品在市场上的应用。(完)

Innovative products in public procurement policy,DaiLiZhong Suggestions,Let the biological medicine field with high technical content/cost-effective/The hospital clinical use of high efficiency/Definite effect,High safety/The price is reasonable new products into the state or province as soon as possible the basic medical insurance/Commercial insurance drug catalogue and the new rural cooperative medical drug directory,And through the price administration departments of audit pricing.Conform to the government procurement of products,Priority on government procurement scope,At the same time in medicine in bidding,In the policy to tilt and priority support,From all aspects to promote innovative products on the market application.(finish)